TR200302242T2 - Protein kinaz önleyicileri olarak pirolopirimidinler - Google Patents

Protein kinaz önleyicileri olarak pirolopirimidinler

Info

Publication number
TR200302242T2
TR200302242T2 TR2003/02242T TR200302242T TR200302242T2 TR 200302242 T2 TR200302242 T2 TR 200302242T2 TR 2003/02242 T TR2003/02242 T TR 2003/02242T TR 200302242 T TR200302242 T TR 200302242T TR 200302242 T2 TR200302242 T2 TR 200302242T2
Authority
TR
Turkey
Prior art keywords
pyrolopyrimidines
protein kinase
kinase inhibitors
prodrugs
oxides
Prior art date
Application number
TR2003/02242T
Other languages
English (en)
Turkish (tr)
Inventor
Paul Cox Joseph
Tahir Majid Nadeem
Amendola Shelly
Stephanie Deprets Daniele
Edlin Chris
Brian Pedgrift Leslie
Halley Frank
Wards Michael
Baudion Bernard
Lain Mclay Mcfarlane
John Aldous David
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of TR200302242T2 publication Critical patent/TR200302242T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
TR2003/02242T 2001-06-23 2002-06-21 Protein kinaz önleyicileri olarak pirolopirimidinler TR200302242T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
US30167801P 2001-06-28 2001-06-28

Publications (1)

Publication Number Publication Date
TR200302242T2 true TR200302242T2 (tr) 2004-12-21

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2003/02242T TR200302242T2 (tr) 2001-06-23 2002-06-21 Protein kinaz önleyicileri olarak pirolopirimidinler

Country Status (22)

Country Link
EP (1) EP1404676A1 (fr)
JP (1) JP4344607B2 (fr)
CN (1) CN1294135C (fr)
AU (1) AU2002314325B8 (fr)
BR (1) BR0210652A (fr)
CA (1) CA2451932C (fr)
CZ (1) CZ20033443A3 (fr)
EA (1) EA007415B1 (fr)
EC (1) ECSP034922A (fr)
EE (1) EE05432B1 (fr)
GB (1) GB0115393D0 (fr)
HU (1) HUP0400300A3 (fr)
ME (1) MEP19308A (fr)
NZ (1) NZ529766A (fr)
OA (1) OA12632A (fr)
PL (1) PL374096A1 (fr)
RS (1) RS51698B (fr)
SK (1) SK15882003A3 (fr)
TN (1) TNSN03144A1 (fr)
TR (1) TR200302242T2 (fr)
UA (1) UA76760C2 (fr)
WO (1) WO2003000695A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
MXPA06005578A (es) 2003-11-17 2006-08-11 Pfizer Prod Inc Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
JP2007512316A (ja) * 2003-11-25 2007-05-17 ファイザー・プロダクツ・インク アテローム性動脈硬化症の治療方法
WO2005105788A1 (fr) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Derives d'indole et leur utilisation en tant qu'inhibiteurs de kinases
FR2876103B1 (fr) * 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
FR2878849B1 (fr) 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
JP2008543855A (ja) 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ， インコーポレイテッド 変形性骨疾患を処置するための方法および組成物
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
DK2348023T5 (da) 2005-12-13 2017-05-15 Incyte Holdings Corp Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
EA201070841A1 (ru) 2008-01-11 2011-02-28 Натко Фарма Лимитед НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
CA2727032C (fr) 2008-06-10 2018-08-14 Abbott Laboratories Composes tricycliques
EP2432472B1 (fr) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- ou heptane-nitrile en tant qu'inhibiteurs de jak
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
WO2011018894A1 (fr) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Dérivés de pyrrolopyrimidine comme modulateurs des canaux potassium
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011029043A1 (fr) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Inhibiteurs hétéroaryles de btk
RU2570416C9 (ru) 2009-12-01 2019-11-25 Эббви Инк. Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
MY178634A (en) 2010-05-21 2020-10-19 Incyte Corp Topical formulation for a jak inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
CN103476776B (zh) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN102093364B (zh) 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2838898B1 (fr) 2012-04-20 2017-01-18 Advinus Therapeutics Limited Composés hétéro-bicycliques substitués, compositions et leurs applications médicinales
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
PL2877467T3 (pl) 2012-07-26 2017-08-31 Glaxo Group Limited 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4
EP2892534B8 (fr) 2012-09-06 2021-09-15 Plexxikon Inc. Composés et procédés pour la modulation des kinases, et leurs indications
WO2014078486A1 (fr) 2012-11-15 2014-05-22 Incyte Corporation Formes galéniques à libération prolongée du ruxolitinib
KR102366356B1 (ko) 2013-03-06 2022-02-23 인사이트 홀딩스 코포레이션 Jak 저해제를 제조하기 위한 방법 및 중간생성물
MX2015012386A (es) 2013-03-13 2016-02-03 Abbvie Inc Inhibidores de la cinasa cdk9.
CN105189481A (zh) 2013-03-13 2015-12-23 艾伯维公司 吡啶cdk9激酶抑制剂
MX2015012153A (es) 2013-03-14 2015-12-01 Abbvie Inc Inhibidores de la quinasa pirrolopirimidina cdk9.
WO2014139328A1 (fr) 2013-03-14 2014-09-18 Abbvie Inc. Inhibiteurs de pyrrolo[2,3-b]pyridine cdk9 kinase
BR112015023187A2 (pt) 2013-03-14 2017-07-18 Abbvie Inc inibidores de pirrolo[2,3 - b] piridina cdk9 kinase
PE20220579A1 (es) 2013-08-07 2022-04-20 Incyte Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1
CN104804001B9 (zh) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
WO2015184305A1 (fr) 2014-05-30 2015-12-03 Incyte Corporation Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
BR112018007677A2 (pt) 2015-10-16 2018-11-06 Abbvie Inc. processos para a preparação de (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)pirrolidina-1-carboxamida e suas formas em estado sólido
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AU2018230500B2 (en) 2017-03-09 2024-03-07 Abbvie Inc. Methods of treating Crohn's disease and ulcerative colitis
WO2019113487A1 (fr) 2017-12-08 2019-06-13 Incyte Corporation Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs
EP4086245A1 (fr) 2018-01-30 2022-11-09 Incyte Corporation Procédés pour fabriquer composés intermediaires pour la synthèse d'un inhibiteur de jak
SG11202009441PA (en) 2018-03-30 2020-10-29 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
AU2019353144B2 (en) 2018-10-05 2023-11-16 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2177925T3 (es) * 1996-01-23 2002-12-16 Novartis Ag Pirrolopirimidinas y procedimientos para su preparacion.
JP2000505109A (ja) * 1996-11-27 2000-04-25 ファイザー・インク 縮合二環式ピリミジン誘導体
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
IL139586A0 (en) * 1998-06-19 2002-02-10 Pfizer Prod Inc PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS
NZ510587A (en) * 1998-09-18 2003-11-28 Abbott Gmbh & Co 4-aminopyrrolopyrimidines as kinase inhibitors
DZ3248A1 (fr) * 1999-12-10 2001-06-14 Pfizer Prod Inc Composés à base de pyrrolo[2,3-d]pyrimidine

Also Published As

Publication number Publication date
ECSP034922A (es) 2004-04-28
CA2451932C (fr) 2009-12-29
CA2451932A1 (fr) 2003-01-03
JP2005508300A (ja) 2005-03-31
CN1518552A (zh) 2004-08-04
TNSN03144A1 (en) 2005-12-23
WO2003000695A1 (fr) 2003-01-03
MEP19308A (en) 2010-06-10
RS99203A (en) 2006-12-15
CZ20033443A3 (en) 2004-03-17
SK15882003A3 (sk) 2004-07-07
EP1404676A1 (fr) 2004-04-07
PL374096A1 (en) 2005-09-19
AU2002314325B8 (en) 2009-01-29
EE200400003A (et) 2004-02-16
BR0210652A (pt) 2004-08-10
CN1294135C (zh) 2007-01-10
RS51698B (en) 2011-10-31
WO2003000695A8 (fr) 2004-03-11
GB0115393D0 (en) 2001-08-15
HUP0400300A3 (en) 2010-12-28
EE05432B1 (et) 2011-06-15
AU2002314325B2 (en) 2009-01-08
EA200400073A1 (ru) 2004-08-26
UA76760C2 (uk) 2006-09-15
HUP0400300A2 (en) 2007-08-28
OA12632A (en) 2006-06-14
EA007415B1 (ru) 2006-10-27
NZ529766A (en) 2008-11-28
JP4344607B2 (ja) 2009-10-14

Similar Documents

Publication Publication Date Title
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
EP1248612A4 (fr) Nouveaux composes et compositions utilises comme inhibiteurs de protease
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
ATE300541T1 (de) Pyrazolopyridinderivate
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
MXPA04005809A (es) Inhibidores de proteinas quinasas.
TR200103457T2 (tr) 4-Fenil-Pirimidin Türevleri.
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
NO20053876L (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.